AICURIS AND CYCLENIUM DEVELOP NOVEL ANTI-INFECTIVES.

 
FREE EXCERPT

AiCuris and Cyclenium Pharma Inc. have signed a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases. The collaboration will capitalize on AiCuris' proven track record in identifying and developing promising anti-infective drug candidates and Cyclenium's novel QUEST Library of next generation synthetic small-molecule macrocycles and unparalleled expertise in drug discovery with such structures.

Within the collaboration, Cyclenium will perform synthetic and medicinal chemistry activities to generate and optimize new macrocyclic molecules effective against specific anti- infective targets chosen by AiCuris. AiCuris will be responsible for pharmacological characterization, further compound optimization, pharmaceutical profiling and development of these new chemical entities. In addition, AiCuris will gain worldwide rights for the development and commercialization of all clinical candidates resulting from this collaboration. In return, Cyclenium will receive an upfront payment, research funding, development and sales milestones, as well as royalties for any marketed products.

We at AiCuris are constantly looking for new approaches and novel compound classes with new modes of action to develop drugs that have the potential to successfully fight the threat of infections of the 21st century, said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures GmbH. We are very impressed by the potential of Cyclenium's CMRT Technology and its QUEST Library of macrocyclic molecules. These compounds constitute a chemical class that provides an attractive alternative to the typical heterocyclic small molecules that dominate current pharmaceutical compound collections.

We are thrilled to begin this collaboration with AiCuris, a leading innovator in the development of medicines to combat infectious diseases, stated Helmut Thomas, Ph.D., President, Chief Executive Officer & Chief Scientific Officer of Cyclenium Pharma. We are very confident that the unique macrocycles produced through our versatile CMRT Technology combined with the superb research team at AiCuris offer excellent potential for the discovery and development of novel anti-infective therapeutics.

Both companies have multiple international partnerships. AiCuris has formed alliances with Merck & Co. (USA), Max Planck Institute of Molecular Physiology (Germany), and is part of an EU funded...

To continue reading

FREE SIGN UP